Breast cancer is a highly heterogeneous malignancy among women worldwide. Traditional prognostic models relying solely on clinicopathological features offer limited predictive accuracy and lack ...

"RethinkBH and Raintree are combining our strengths to deliver tools that meet the real-world needs of multidisciplinary therapy practices," said Rethink CEO Ben Semmes. "We want to make life easier ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers ...

Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial ...

Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsGregory Demopulos - Co-Founder, Chairman, CEO ...

Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and ...

Third quarter 2025 revenue grew more than tenfold year-over-year and 30% sequentially quarter-over-quarter, demonstrating ...

While FDA reviews PMA application for the upcoming Perimeter B-Series (Company continues to anticipate Agency's decision in H1-2026) , commercial market ...

While FDA reviews PMA application for the upcoming Perimeter B-Series (Company continues to anticipate Agency's decision in H1-2026), commercial market traction with ...

Introduction Burnout and reduced well-being are highly prevalent among Japanese medical students during clinical training. Scalable, evidence-based interventions are urgently needed. This protocol ...

AM Eastern time on Thursday, November 13, 2025 Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – November 12, 2025) – Medexus Pharmaceuticals ...